OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-06-23
Last Posted Date
2015-04-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
252
Registration Number
NCT01149655
Locations
πŸ‡¨πŸ‡³

Study Site, Taoyuan County, Taiwan

Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder

Completed
Conditions
First Posted Date
2010-06-16
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
501
Registration Number
NCT01145313

The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use

Completed
Conditions
First Posted Date
2010-06-10
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
48865
Registration Number
NCT01141400

Outcomes in MEasurement-Based Treatment

Completed
Conditions
First Posted Date
2010-06-10
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
914
Registration Number
NCT01141387

Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

First Posted Date
2010-05-26
Last Posted Date
2021-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
10
Registration Number
NCT01131351
Locations
πŸ‡±πŸ‡Ή

Hospital for Tuberculosis and Lung Diseases, Siauliai, Lithuania

πŸ‡±πŸ‡»

Infectology Center of Latvia - Clinic of Tuberculosis and Lung Diseases, Ogre, Latvia

πŸ‡±πŸ‡Ή

National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-05-25
Last Posted Date
2020-01-06
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
709
Registration Number
NCT01129882

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

First Posted Date
2010-05-13
Last Posted Date
2016-02-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
524
Registration Number
NCT01122927
Locations
πŸ‡ΊπŸ‡¦

Study Site, Vinnytsya, Ukraine

πŸ‡ΊπŸ‡¦

Study Site 2, Kharkiv, Ukraine

πŸ‡ΊπŸ‡¦

Study Site 1, Kharkiv, Ukraine

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-10-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
237
Registration Number
NCT01111552
Locations
πŸ‡·πŸ‡΄

Study Site 1, Bucuresti, Romania

πŸ‡·πŸ‡΄

Study Site 2, Bucuresti, Romania

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-12-21
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
137
Registration Number
NCT01111565
Locations
πŸ‡ΏπŸ‡¦

Study Site 1, Cape Town, South Africa

πŸ‡ΏπŸ‡¦

Study Site 2, Cape Town, South Africa

Β© Copyright 2024. All Rights Reserved by MedPath